ChemioCare planning to IPO and raise funds to bring 'transformative' drug to the market
ChemioCare CEO Pedro Lichtinger tells Proactive Investors the bio-pharmaceutical company is focused on treating the side effects of chemotherapy.
Founded around one year ago, Lichtinger says the company’s transdermal patch technology will help cancer patients going through chemotherapy to experience significantly less side effects of the drug including less nausea and vomiting.
Lichtinger says the company is planning to go public and list on the Nasdaq and the TSX in around 10 months, using the capital raised to run the clinical trials for the drug.
Story by ProactiveInvestors